Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries. Issue 11 (30th November 2022)

• Record Type: Journal Article
• Authors: Cortellini, Alessio; Dettorre, Gino M; Dafni, Urania; Aguilar-Company, Juan; Castelo-Branco, Luis; Lambertini, Matteo; Gennatas, Spyridon; Angelis, Vasileios; Sita-Lumsden, Ailsa; Rogado, Jacobo; Pedrazzoli, Paolo; Viñal, David; Prat, Aleix; Rossi, Maura; Berardi, Rossana; Alonso-Gordoa, Teresa; Grisanti, Salvatore; Dimopoulou, Georgia; Queirolo, Paola; Pradervand, Sylvain; Bertuzzi, Alexia; Bower, Mark; Arnold, Dirk; Salazar, Ramon; Tucci, Marco; Harrington, Kevin J; Mazzoni, Francesca; Mukherjee, Uma; Tsourti, Zoi; Michielin, Olivier; Pommeret, Fanny; Brunet, Joan; Vincenzi, Bruno; Tonini, Giuseppe; Patriarca, Andrea; Biello, Federica; Krengli, Marco; Tabernero, Josep; Pentheroudakis, George; Gennari, Alessandra; Peters, Solange; Romano, Emanuela; Pinato, David J;
• Is Part Of: Journal for immunotherapy of cancer. Volume 10:Issue 11(2022)
• Publication Date: 2022-11-30
• Subjects: COVID-19 -- Vaccination -- Immunogenicity, Vaccine -- Cytotoxicity, Immunologic -- Immunotherapy; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2022-005732
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer. Methods: In a joint analysis of ICI recipients from OnCovid (NCT04393974 ) and European Society for Medical Oncology (ESMO) CoCARE registries, we assessed severity and mortality from SARS-CoV-2 in vaccinated and unvaccinated patients with cancer and explored whether prior immune-related adverse events (irAEs) influenced outcome from COVID-19. Findings: The study population consisted of 240 patients diagnosed with COVID-19 between January 2020 and February 2022 exposed to ICI within 3 months prior to COVID-19 diagnosis, with a 30-day case fatality rate (CFR30 ) of 23.6% (95% CI 17.8 to 30.7%). Overall, 42 (17.5%) were fully vaccinated prior to COVID-19 and experienced decreased CFR30 (4.8% vs 28.1%, p=0.0009), hospitalization rate (27.5% vs 63.2%, p<0.0001), requirement of oxygen therapy (15.8% vs 41.5%, p=0.0030), COVID-19 complication rate (11.9% vs 34.6%, p=0.0040), with a reduced need for COVID-19-specific therapy (26.3% vs 57.9%, p=0.0004) compared with unvaccinated patients. Inverse probability of treatment weighting (IPTW)-fitted multivariable analysis, following a clustered-robust correction for the data source (OnCovid vs ESMO CoCARE), confirmed that vaccinated patients experienced a decreased risk of death at 30 days (adjusted OR, aOR 0.08, 95% CI 0.01 to 0.69). Overall, 38 patients (15.8%) experienced at least one irAE of any grade at any time prior to COVID-19, at a median time of 3.2 months (range 0.13–48.7) from COVID-19 diagnosis. IrAEs occurred independently of baseline characteristics except for primary tumor (p=0.0373) and were associated with a significantly decreased CFR30 (10.8% vs 26.0%, p=0.0462) additionally confirmed by the IPTW-fitted multivariable analysis (aOR 0.47, 95% CI 0.33 to 0.67). Patients who experienced irAEs also presented a higher median absolute lymphocyte count at COVID-19 (1.4 vs 0.8 10 9 cells/L, p=0.0098). Conclusion: Anti-SARS-CoV-2 vaccination reduces morbidity and mortality from COVID-19 in ICI recipients. History of irAEs might identify patients with pre-existing protection from COVID-19, warranting further investigation of adaptive immune determinants of protection from SARS-CoV-2.